[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527704":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":40,"centralContacts":45,"locations":51,"responsibleParty":68,"collaborators":10,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":10,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":10,"enrollmentInfo":79,"targetDuration":82,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":10,"overallStatus":53,"whyStopped":10,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Tier 1",null,"* Participants with Peutz-Jeghers syndrome and\u002For carriers of a germline CDKN2A mutation and\u002For hereditary pancreatitis with PRSS1 mutation and clinical history of pancreatitis(age ≥40 or 10 years younger than youngest affected blood relative)\n* Carriers of a germline BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation with at least one affected first-degree blood relative (age ≥45 or 10 years younger than youngest affected blood relative)\n* At least one first-degree relative (FDR) with pancreatic cancer who in turn also has a first-degree relative with pancreatic cancer and\u002For at least two affected blood relatives on the same side of the family, of whom at least one is an FDR to the individual and\u002For at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual(age ≥50 or 10 years younger than youngest affected blood relative)",[13,14],"Other: Bio-specimen Collection: Blood","Other: Bio-specimen Collection: Pancreatic Juice",{"label":16,"type":10,"description":17,"interventionNames":18},"Tier 2","* Individual with family history of PDAC in only one first degree relative (FDR); age ≥50 or 10 years younger than the affected first degree relative\n* OR known BRCA2, BRCA1, PALB2, ATM, MLH1, MSH2, or MSH6 gene mutation; age \\> 45 who do not meet tier 1 criteria.",[13,14,19],"Diagnostic Test: MRI",[21,27,33],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Bio-specimen Collection: Blood","At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.",[9,16],[26],"Blood Draw",{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Bio-specimen Collection: Pancreatic Juice","This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.",[9,16],[32],"Pancreatic Juice Collection",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"DIAGNOSTIC_TEST","MRI","A research MRI with contrast that includes a Magnetic Resonance Cholangiopancreatography (MRCP) will be offered to patients in the Tier 2 cohort at baseline and at 3-year intervals if not done as standard of care. Gadolinium based intravascular contrast will be administered for this procedure. Sedation for claustrophobia\u002Fanxiety per clinical protocol will be an option if the patients requested. Subject would be notified of any concerning results. A safety questionnaire will be completed by the study team before ordering the MRI.\n\nClinically indicated MRIs for the TIER 1 participants will be used and collected as part of the registry.\n\nIf a clinical MRI\u002FMRCP has been performed between 0 to 3 months before obtaining consent, the prior clinical MRI\u002FMRCP could be used to obtain baseline imaging data.",[16],[39],"Magnetic Resonance Imaging",[41],{"name":42,"affiliation":43,"role":44},"Shounak Majumder, M.D.","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[52],{"facility":43,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-92.4699,44.02163,{"lat":63,"lon":62},[66,67],{"name":47,"role":48,"phone":49,"phoneExt":10,"email":50},{"name":42,"role":44,"phone":10,"phoneExt":10,"email":10},{"type":69,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100527704","a-prospective-registry-for-patients-at-high-risk-for-pancreatic-cancer-100527704",false,"NCT06151223","A Prospective Registry for Patients at High-Risk for Pancreatic Cancer","Inclusion Criteria:\n\n* Age ≥ 18 year\n* Able to provide written informed consent\n* Meets criteria as a High-Risk Individual as defined by protocol\n\nExclusion Criteria:\n\n* Individual who has a personal history of pancreatic ductal adenocarcinoma (PDAC)\n* History of total pancreatectomy",true,"ALL","18 Years",{"count":80,"type":81},5000,"ESTIMATED","10 Years","OBSERVATIONAL","This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC) and to facilitate the use of state-of-the-art machine learning-based algorithms that utilize databases and images with the purpose of identifying early stages of pancreatic cancer, as well as people at high-risk.The study also aims to provide a platform for development of an interventional protocol for early detection of PDAC.",[86,87,88,89],"Pancreatic Cancer","Pancreatic Ductal Adenocarcinoma","PDAC","PDAC - Pancreatic Ductal Adenocarcinoma","2026-03-06",{"date":92,"type":93},"2026-03-10","ACTUAL",{"date":95,"type":93},"2021-07-13",{"date":97,"type":81},"2031-07-31",{"name":5,"class":6},1]